Quanterix Loses $0.46 per Share and Narrows 2026 Revenue Guidance
Key Facts
Quanterix reported a GAAP loss of $0.46 per share in the third quarter of 2026, exceeding analysts’ estimated loss of $0.43 per share by $0.03, according to StreetInsider data. The result was mixed: the company continued to post losses, but said its net loss narrowed to $21.6 million, an improvement of 35.6% from the same period a year earlier. Meanwhile, total revenue fell to $34.974 million from $40.233 million in the third quarter of 2025. The company said revenue rose 6.3% from the previous quarter despite continued market weakness. QTRX shares closed at $2.9 on November 6, 2026.
The quarter-over-quarter comparison shows revenue improving after second-quarter results, when the company reported $32.9 million, up 34% year over year from $24.5 million in the second quarter of 2025. But management said in its announcement for that quarter that revenue came in below its expectations because of execution challenges and continued market weakness. In its third-quarter results, the company described the sequential improvement as broad-based; Chief Executive Everett Cunningham said, "This first step toward returning to growth reflects sequential improvement across all of our businesses." The company linked the next phase to reorganizing teams and adding commercial leadership and expertise, saying this should accelerate execution in the fourth quarter and beyond. This trajectory puts quarterly revenue growth against the continued market weakness acknowledged by the company.
On operating profitability, the GAAP operating loss was about $22.496 million in the third quarter, compared with $37.325 million in the same period of 2025. The company also reported a non-GAAP adjusted EBITDA loss of $12.2 million, down 2.4% from the year-earlier loss. Margin indicators were mixed: the GAAP gross margin was 38.6%, down 90 basis points year over year, while the adjusted gross margin reached 47.4%, up 150 basis points. In the nine months ended September 30, 2026, the company recorded impairment and restructuring expenses of $49.442 million, compared with $14.844 million in the same period of 2025. It said the expenses included impairment of goodwill and an intangible asset, as well as one-time employee separation costs.
Quanterix ended the third quarter with $80.7 million in cash and cash equivalents, marketable securities and restricted cash. The company narrowed its 2026 revenue guidance to a range of $142 million to $146 million. It also maintained its guidance for a non-GAAP adjusted gross margin of 48% to 50%. The company expects to end the year with about $70 million in cash and no debt. The outlook comes as the quarter’s results point to sequential revenue improvement alongside continued losses and a year-over-year decline in total revenue.
In its diagnostics business, the company said that, effective November 1, 2026, traditional Medicaid beneficiaries and Florida state employees became eligible for coverage of qualifying blood biomarker tests, including LucentAD Complete, when medically necessary. The company is scheduled to ship its high-plex TIME and ADC panels in early 2027. It said the TIME panel provides a broader view of the tumor immune environment, while the ADC panel relates to antibody-drug conjugates. Regarding the results announcement, Quanterix said its conference call would be held on November 9, 2026, at 8:30 a.m. Eastern time. It added that a recording of the webcast would remain available on its website for one year.